Anterior Uveitis Market Report 2026

The anterior uveitis market size has grown rapidly in recent years. It will grow from $0.57 billion in 2025 to $0.64 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to improved ophthalmic diagnostic capabilities, increased prevalence of autoimmune-related eye disorders, wider availability of corticosteroids, expansion of eye care infrastructure, growth in specialist ophthalmology services.

The anterior uveitis market size is expected to see rapid growth in the next few years. It will grow to $0.98 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to rising demand for biologic eye therapies, increasing integration of precision diagnostics, expansion of advanced ophthalmic drug pipelines, growing focus on vision preservation, increasing investment in inflammatory eye disease research. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of advanced diagnostic biomarkers, growing preference for targeted immunosuppressive treatments, expansion of outpatient ophthalmic care, enhanced focus on early disease detection.

The increasing prevalence of autoimmune diseases is expected to fuel the growth of the anterior uveitis market in the coming years. Autoimmune diseases arise when the immune system mistakenly targets the body's healthy cells and tissues, perceiving them as foreign threats. This abnormal immune response results in inflammation and damage across various organs and systems. The rise in autoimmune diseases is attributed to genetic predispositions, environmental influences, lifestyle changes, and improved awareness, which has led to better diagnosis. Anterior uveitis frequently occurs as a manifestation of autoimmune diseases, causing inflammation in the eye's anterior segment, and is often linked with conditions such as rheumatoid arthritis and ankylosing spondylitis. For example, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organisation supporting individuals with arthritis and musculoskeletal conditions, by 2025, around 562,378 Australians are expected to be living with rheumatoid arthritis (RA), representing 14% of the total arthritis population. Consequently, the growing prevalence of autoimmune diseases is contributing to the expansion of the anterior uveitis market.

Major companies operating in the anterior uveitis market are concentrating on developing advanced drug formulations, such as eye drops, to enhance patient adherence, improve drug delivery, and reduce inflammation with minimal side effects. Eye drops are commonly used in anterior uveitis treatment to control inflammation, relieve pain, and prevent potential complications. For example, in January 2024, Tarsier Pharma Ltd., an Israel-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the clinical trial protocol and statistical analysis plan of the Tarsier-04 Phase 3 trial. This trial is designed to assess the effectiveness of TRS01 eye drops in treating non-infectious uveitis, including uveitic glaucoma. The Tarsier-04 trial is a multicenter, randomized, double-masked, active-controlled study enrolling up to 300 patients in the U.S., aiming to demonstrate TRS01’s safety and efficacy, particularly in controlling inflammation without raising the risk of glaucoma.

In January 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Oxular Limited for an undisclosed sum. This acquisition gives Regeneron access to an advanced delivery device for ocular gene therapies, speeding up its progress toward clinical readiness. By leveraging Oxular’s proprietary technologies, Regeneron is positioned to enhance therapeutic precision and drive innovation in eye care. Oxular Limited is a UK-based biotech company focused on developing drug and device treatments for retinal disorders, including anterior uveitis.

Major companies operating in the anterior uveitis market are AbbVie Inc, Novartis AG, Bausch Health Companies Inc, EyePoint Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Clearside Biomedical Inc, Eyegate Pharmaceuticals Inc, Horizon Therapeutics Plc, Mylan NV, Sun Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, Pfizer Inc, Amgen Inc, Sanofi, Galapagos NV, Tarsier Pharma Ltd, TopiVert Ltd, Ocular Therapeutix Inc, Ophthotech Corporation, Aciont Inc, Sirion Therapeutics Inc, Aldeyra Therapeutics Inc, Kiora Pharmaceuticals Inc, UCB SA, ANI Pharmaceuticals Inc, Priovant Therapeutics, Roivant Sciences Inc, Active Biotech.

North America was the largest region in the anterior uveitis market in 2025. The regions covered in the anterior uveitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anterior uveitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the anterior uveitis market by increasing costs of imported biologics, corticosteroids, diagnostic imaging devices, and surgical equipment used in ophthalmic care. Hospitals and ambulatory surgical centers in North America and Europe are most affected due to reliance on imported specialty drugs and devices, while Asia-Pacific faces higher costs for advanced diagnostics. These tariffs elevate treatment and procedure expenses. However, they also promote domestic drug formulation, localized ophthalmic device production, and regional clinical research investment.

The anterior uveitis market research report is one of a series of new reports that provides anterior uveitis market statistics, including anterior uveitis industry global market size, regional shares, competitors with a anterior uveitis market share, detailed anterior uveitis market segments, market trends and opportunities, and any further data you may need to thrive in the anterior uveitis industry. This anterior uveitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anterior uveitis is a condition that causes inflammation of the eye's middle layer, which comprises the iris (the colored part of the eye) and the adjacent ciliary body. It can develop as a result of eye trauma, such as a direct impact or the presence of a foreign object in the eye. Additionally, it may be associated with systemic health conditions like rheumatoid arthritis, syphilis, tuberculosis, sarcoidosis, or viral infections (herpes simplex, herpes zoster, cytomegalovirus), or it may be idiopathic, with no identifiable underlying cause.

The primary treatment approaches for anterior uveitis include pharmacological therapies, surgical interventions, and biologic treatments. Pharmacological therapies consist of administering medications to reduce inflammation and manage symptoms. Diagnosis methods encompass clinical evaluation, diagnostic imaging, and biomarker testing. The condition may result from infectious or non-infectious causes and is relevant in hospitals, clinics, and ambulatory surgical centers.

The anterior uveitis market consists of revenues earned by entities by provide services such as slit-lamp examinations, optical coherence tomography (OCT), ultrasound biomicroscopy, corticosteroid administration, and glaucoma management. The market value includes the value of related goods sold by the service provider or included within the service offering. The anterior uveitis market also includes sales of corticosteroids (topical and systemic), non-steroidal anti-inflammatory drugs (NSAIDS), and immunosuppressive drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.